Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: A pilot study

P. Queirolo, A. Morabito, S. Laurent, S. Lastraioli, P. Piccioli, P. A. Ascierto, G. Gentilcore, M. Serra, A. Marasco, E. Tornari, B. Dozin, M. P. Pistillo

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

CTLA-4 blockade with monoclonal antibodies can lead to cancer regression in patients with metastatic melanoma (MM). CTLA-4 gene polymorphisms may influence the response to anti-CTLA-4 antibodies although few data are available regarding this issue. We analyzed six CTLA-4 single nucleotide polymorphisms (-1661A>G,-1577G>A,-658C>T,-319C>T, +49A>G, and CT60G>A) in 14 Italian MM patients and 45 healthy subjects. We found a significant association between the-1577G/A and CT60G/A genotypes and improved overall survival (Pc < 0.006, Bonferroni corrected), further confirmed by the diplotype analysis (-1577&CT60 GG-AA diplotype, p < 0.001). A positive trend toward an association between these genotypes and response to therapy was also observed.

Original languageEnglish
Pages (from-to)336-345
Number of pages10
JournalCancer Investigation
Volume31
Issue number5
DOIs
Publication statusPublished - 1 Jun 2013
Externally publishedYes

    Fingerprint

Keywords

  • CTLA-4
  • CTLA-4 blockade
  • Melanoma
  • Overall survival
  • Single nucleotide polymorphisms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Queirolo, P., Morabito, A., Laurent, S., Lastraioli, S., Piccioli, P., Ascierto, P. A., Gentilcore, G., Serra, M., Marasco, A., Tornari, E., Dozin, B., & Pistillo, M. P. (2013). Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: A pilot study. Cancer Investigation, 31(5), 336-345. https://doi.org/10.3109/07357907.2013.793699